Background CXCR7 (RDC1), the recently discovered second receptor for CXCL12, is
phylogenetically closely related to chemokine receptors, but fails to couple to G-proteins and to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), …

Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2
infection is crucial for understanding immune protection and identifying targets for …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded
in some areas by the higher transmission potential of the B.1.1.7 variant 1 , which has …

A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has
become a public health emergency. By characterizing memory lymphocytes from ZIKV-…